Noticias de PCVX_US

Mercado

Noticias del mercado

Últimas noticias sobre PCVX_US — 247 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PCVX_US ✕ 247 resultados
06/10/2026 PCVX_US — RTTNews
Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5%
06/10/2026 PCVX_US — RTTNews
Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5%
06/10/2026 PCVX_US — Investing.com
Vaxcyte prices $1 billion dual offering of stock and notes
06/10/2026 PCVX_US — Benzinga
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
06/10/2026 PCVX_US — GlobeNewswire
Vaxcyte Announces Pricing of Concurrent Public Offerings of
06/10/2026 PCVX_US — Seeking Alpha
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
06/10/2026 PCVX_US — The Business Journals
Vaccine developer looks to raise $1 billion after successful clinical trial
06/10/2026 PCVX_US — GuruFocus
Vaxcyte (PCVX) Announces $1 Billion Concurrent Offering Includin
06/10/2026 PCVX_US — Investing.com
Vaxcyte stock hits 52-week high at 87.21 USD By Investing.com
06/10/2026 PCVX_US — Investing.com
Why is Vaxcyte stock sliding in after-hours trading today? By Investing.com
05/10/2026 PCVX_US — Investing.com
Vaxcyte announces $1 billion dual public offering
05/10/2026 PCVX_US — Yahoo Finance
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.

05/10/2026 PCVX_US — Investing News Network
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
05/10/2026 PCVX_US — StreetInsider
Vaxcyte launches $1B in dual public offerings of stock and notes
05/10/2026 PCVX_US — Investing.com
Why is Vaxcyte stock sliding in after-hours trading today? By Investing.com
05/10/2026 PCVX_US — STAT
Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

05/10/2026 PCVX_US — Investing.com
Vaxcyte stock hits 52-week high at 87.21 USD By Investing.com
05/10/2026 PCVX_US — MarketScreener
Vaxcyte Launches $1 Billion Offerings of Stock, Prefunded Warrants, 2032 Notes
05/10/2026 PCVX_US — GuruFocus
Vaxcyte (PCVX) Launches $1 Billion Equity and Debt Offering to F
05/10/2026 PCVX_US — Investing.com
Vaxcyte stock falls on $1B dual offering launch

Página 5 de 13